PE-Labeled Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Tetramer Protein
Catalog No: HLAA0201-HP012
- Species
- Human
- Expression System
- E. coli
- Tag
- His, Avi
Product overview
Recombinant PE-Labeled Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Tetramer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. PE-Labeled Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and CLAVEEVSL peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &CLAVEEVSL).
Product Details
- Molecular Aliases
- NPM1-CLAV (CLAVEEVSL); NPM1-CLAV; CLAVEEVSL;
- Protein Length
- Gly25-Thr305
- Expression System
- E. coli
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl, 0.2% BSA (pH 8.0).
- State
- Liquid
- Storage Conditions
- Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background
The nucleophosmin (NPM1) mutant protein, a leukemia-associated antigen characterized by its leukemia-restricted expression and immunogenic potential, has emerged as a promising therapeutic target for acute myeloid leukemia (AML) immunotherapy. Among its immunogenic epitopes, the CLAVEEVSL peptide derived from the full C-terminal region of the NPM1-mutated isoform demonstrates potent immunogenicity, making it a prime candidate for T cell-based immunotherapies.
References
- [1] Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. DOI: 10.18632/oncotarget.26617
- [2] Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. DOI: 10.3390/ijms22179159
Have questions about this product?
Our technical team can help with product selection, application questions and order support.